Satovsky Asset Management LLC Has $356,000 Stake in Johnson & Johnson (NYSE:JNJ)

Satovsky Asset Management LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,480 shares of the company’s stock after selling 116 shares during the quarter. Johnson & Johnson comprises 0.1% of Satovsky Asset Management LLC’s portfolio, making the stock its 27th biggest holding. Satovsky Asset Management LLC’s holdings in Johnson & Johnson were worth $356,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. IFS Advisors LLC raised its position in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after purchasing an additional 100 shares during the period. Highline Wealth Partners LLC acquired a new stake in Johnson & Johnson during the third quarter worth approximately $31,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Johnson & Johnson in the third quarter valued at approximately $35,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $32,000. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its stake in Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after purchasing an additional 91 shares during the period. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research reports. Raymond James dropped their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Leerink Partners dropped their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Citigroup lowered their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company cut their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $162.35 on Friday. The firm’s fifty day moving average price is $148.93 and its two-hundred day moving average price is $155.88. The stock has a market cap of $390.87 billion, a PE ratio of 24.41, a PEG ratio of 2.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the prior year, the firm earned $2.29 EPS. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.06%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.